Discrepancies Between Nomenclature and Indications of Psychotropics

Abstract

Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications.

Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts.

Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan.

Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.

Key words

antidepressant - antipsychotic - indication - NbN - neuroscience-based nomenclature

• References

• 1 Calabrese JR, Sanchez R, Jin N. et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: A double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017; 78: 324-331
• 2 Uchida H. Neuroscience-based nomenclature: What is it, why is it needed, and what comes next?. Psychiatry Clin Neurosci 2018; 72: 50-51
• 3 Otsuka Pharmaceutical Co. L. Package insert of Abilify.
• 4 Pfizer. Prescribing information for Zoloft.
• 5 Zohar J, Stahl S, Moller HJ. et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol 2015; 25: 2318-2325
• 6 Uchida H, Fleischhacker W, Juckel G. et al. Naming for psychotropic drugs: Dilemma and challenge. Pharmacopsychiatry 2017; 50: 1-2
• 7 Nagai N, Tani H, Suzuki T. et al. Patients’ knowledge about prescribed antipsychotics and medication adherence in schizophrenia: A cross-sectional survey. Pharmacopsychiatry 2017; 50: 264-269
• 8 Buchanan RW, Kreyenbuhl J, Kelly DL. et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93
• 9 Argo TR, Crismon ML, Miller AL, Moore TA, Bendele SD, Suehs B. Texas Medication Algorithm Project Procedural Manual. Schizophrenia Treatment Algorithm. Texas Department of State Health Services, 2008.
• 10 Schulze TG, Akula N, Breuer R. et al. Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. World J Biol Psychiatry 2014; 15: 200-208
• 11 Kim E, Howes OD, Park JW. et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychol Med 2016; 46: 357-366
• 12 Friedhoff AJ, Simkowitz P. A new conception of the relationship between psychological coping mechanisms and biological stress buffering systems. Br J Psychiatry Suppl 1989; 61-66
• 13 Zohar J, Nutt DJ, Kupfer DJ. et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 2014; 24: 1005-1014